Computer-extracted MR imaging features are associated with survival in glioblastoma patients

Size: px
Start display at page:

Download "Computer-extracted MR imaging features are associated with survival in glioblastoma patients"

Transcription

1 Computer-extracted MR imaging features are associated with survival in glioblastoma patients Maciej A. Mazurowski, Ph.D. 1, Jing Zhang, Ph.D. 1, Katherine B. Peters, M.D., Ph.D. 2, Hasan Hobbs, M.D. 1 Affiliation: 1. Duke University Medical Center Department of Radiology 2301 Erwin Road, Box 3808 Durham, NC Duke University School of Medicine Department of Neurology Durham, NC Corresponding Author: Maciej A. Mazurowski, Ph.D maciej.mazurowski@duke.edu Phone: (919) Fax: (919) NOTE: This is the accepted version of the article prior to proof editing. The final version of the article can be found at 1

2 ABSTRACT Background: Automatic survival prognosis in glioblastoma (GBM) could result in improved treatment planning for the patient. The purpose of this research is to investigate the association of survival in GBM patients with tumor features in pre-operative magnetic resonance (MR) images assessed using a fully automatic computer algorithm. Methods: MR imaging data for 68 patients from two US institutions were used in this study. The images were obtained from the Cancer Imaging Archive. A fully automatic computer vision algorithm was applied to segment the images and extract 8 imaging features from the MRI studies. The features included tumor side, proportion of enhancing tumor, proportion of necrosis, T1/FLAIR ratio, major axis length, minor axis length, tumor volume, and thickness of enhancing margin. We constructed a multivariate Cox proportional hazards regression model and used a likelihood ratio test to establish whether the imaging features are prognostic of survival. We also evaluated the individual prognostic value of each feature through multivariate analysis using the multivariate Cox model and univariate analysis using univariate Cox models for each feature. Results: We found that the automatically extracted imaging features were associated with survival (p=0.031). Multivariate analysis of individual features showed that two individual features were predictive of survival: proportion of enhancing tumor (p=0.013), and major axis length (p=0.026). Univariate analysis indicated the same two features as significant (p=0.021, and p=0.017 respectively). Conclusion: Computer-extracted MR imaging features can be used for survival prognosis in GBM patients. Key words: Glioblastoma, MRI, survival, computer vision 2

3 Introduction Glioblastoma (GBM) is the most common [1] and the most aggressive primary brain tumor [2, 3]. The 1-year survival rate is 50.6% [3], and the 5-year survival rate is 9.8% [2]. While the prognosis is usually poor in this population, there is a subset of patients that experience a better prognosis and can have long-term survival (as defined by > 5 years from time of diagnosis). In light of these differences, biomarkers for survival prognosis could be of high utility. One of the benefits of such biomarkers is the improved selection of patients for clinical trials. Different variables have been shown to be associated with survival in GBM. Clinical features predictive of time to death include Karnofsky Performance Status (KPS) [4, 5] and age [4]. Extent of resection is also associated with survival such that gross total resection is associated with a better prognosis [4]. Recently, prognostic and predictive biomarkers for GBM based on genetic information have been developed [6]. Examples include a gene expression-based tumor classification by Verhaak et al [7] which was shown to be associated with patient survival and response to aggressive therapy, as well as a multi-gene biomarker for survival prognosis presented by Colman et al [8]. Mutations in isocitrate dehydrogenase 1 (IDH1) [9] and methylguanine methyl transferase (MGMT) promoter methylation [10-12] are now commonly tested and used prognostically but it remains to be seen if they can be predictive for survival time in patients with GBM. Prognostic biomarkers based medical imaging have been explored to a lesser extent. However, the research in this direction is gaining momentum. Lacroix et al [4] has shown that 4 out of 7 of the examined imaging features were associated with survival. These features were: tumor functional grade, necrosis grade, edema grade, and enhancement grade. Studies by Pope et al [13], Park et al [5], and Zinn et al [14] provided more evidence for the usefulness of imaging features when predicting survival time. Recently, two studies by Gutman et al [15], and Mazurowski et al [16] used a standardized lexicon of imaging features extracted from MRI scans called VASARI and showed that such features are predictive of survival. Survival prognosis through the utilization of standard of care preoperative imaging would be of value as it captures phenotypical properties of the tumor that might not be currently fully identified by other biomarkers. Furthermore, it does not require conducting any additional tests as the imaging information is already available through standard of care imaging. The disadvantage is a significant additional workload for radiologists and therefore additional cost of 3

4 the test incurred by the time consuming feature assessment. Furthermore, the interobserver variability [15] in the feature assessment could negatively affect the usefulness of such features. In this study, we address this shortcoming of medical imaging biomarkers for GBM and propose a biomarker for survival prognosis that is based on MR imaging features extracted automatically using computer algorithms. Since the imaging features are extracted in a fully automatic manner and the survival prognosis is done using a computer model, such survival prognosis could be provided automatically to the clinician interpreting/ordering the imaging exam. This study is a proof of concept for such an approach. Specifically, in this pilot study, we automatically extracted 8 features and demonstrated that they were associated with survival. Additional benefits of a computerized biomarker are a lack of interobserver variability (i.e. the algorithm always provides the same response to a given image) and precision of the measurements. This is the first study that demonstrates that fully automatically extracted MR imaging features are predictive of survival. However, there are some results in the literature that are related to our finding. The closest one is in the paper by Zacharaki et al [17], where the authors examined a decision tree for predicting survival that used manually extracted features, and semiautomatically extracted features (tumor segmentation was aided by experts). In their univariate analysis, the authors showed a relationship between some simple intensity-based features (such as mean intensity) of two tumor compartments distinguished by the authors observed in DTI for high grade glioma patients (a portion were GBM patients). Another very recent study [18] applied automatically extracted MR imaging features for survival prediction in 16 patients but did not provide statistical analysis that allowed a determination of the association between those features and survival. Multiple other studies, for example [19],[20], and [21] present computer algorithms for the segmentation of brain tumors (some of them into different compartments) but those studies do not offer an evaluation of such methods in the context of survival prognosis. 4

5 Materials and Methods Patient Population Our patient population consisted of 68 GBM patients. Out of the 68 patients, 22 were from MD Anderson Cancer Center and 46 were from Henry Ford Hospital. For each patient, preoperative MR imaging data as well as survival data were available. The patient survival data was obtained from the Cancer Genome Atlas (TCGA, The two databases are correlated through unique identifiers. The list of identifiers for patients used in our study can be accessed at the following link: patients-list.txt. Imaging Data The patient imaging data was downloaded from the Cancer Imaging Archive (TCIA, For each patient, three MR imaging sequences were available. The sequences were: (1) T1-weighted pre contrast sequence, (2) T1-weighted post contrast sequence, and (3) FLAIR. More information about the imaging data can be found on the TCIA website ( The images were preoperative. We annotated different tumor components in each slice where a tumor occurs. All annotations were approved by a neuroradiology fellow at our institution. The annotations were used to train our segmentation algorithm. Algorithm for extracting imaging features The imaging features used in our study were extracted using a computer algorithm developed in our laboratory and presented in another, accompanying publication [22] which focuses on the details of the algorithm, comparison of the automatic and manual segmentations, and comparison between the values of the extracted features and their reference standard. The first step of the algorithm was automatic segmentation of the tumor into four mutually exclusive compartments: (C1) necrosis, (C2) enhancing tumor, (C3) T1 abnormality excluding C1 and C2, (C4) FLAIR abnormality excluding T1 abnormality. Fig. 1 shows the four tumor compartments. The segmentation was done by applying a random forest classifier to each voxel in order to classify it into one of the four tumor compartment (or as normal). The classifier used 219 low-level descriptors extracted for each voxel based on the three available imaging sequences (the 5

6 sequences were registered prior to segmentation). More details on this algorithm can be found in [22], where we evaluate the performance of the segmentation algorithm in detail including measurements of agreement between manual and our automatic segmentations using Dice coefficient. After the tumors were identified in the images and segmented into different compartments, high level imaging features were extracted as described below. Fig. 1 Tumor segmentation into different compartments: C1 : enhancing region; C2 : necrotic region; C3 : T1 abnormality (hypo-intensity region on T1) excluding enhancing and necrotic regions; C4 : FLAIR abnormality (hyper-intensity region on FLAIR) excluding T1 abnormality. Figure (A) shows the manually annotated compartments. Figure (B) shows the compartments as classified by our segmentation algorithm. Figure (C) shows the original post contrast T1-weighted slice. Imaging features Based on the tumor segmentation provided by our algorithm described above, we extracted 8 imaging features for each case. These were features that we could reliably extract based on our automatic segmentation algorithm and were potentially predictive of survival. These features were: tumor side, proportion of enhancing tumor, proportion of necrosis, T1/FLAIR ratio, major axis length, minor axis length, tumor volume, and thickness of enhancing margin. The proportion of necrosis and proportion of enhancing tumor were calculated as the volumes of the respective compartments divided by the volume of the sum of all compartments. The T1/FLAIR ratio was calculated as the proportion of the total volume of tumor compartments C1, C2, and C3, and the total volume of all tumor compartments. The volume, major axis length, and minor axis length 6

7 were calculated for the entire tumor understood as the sum of all compartments. The thickness of the enhancing margin was assigned a value of 0 if the tumor was solidly enhancing. Experimental design and statistical analysis First, we applied a well-known leave-one-out cross validation approach to automatically extract imaging features. Specifically, we used all but one case to train our feature extraction algorithm which involved a random forest classifier. Then, we applied the trained algorithm to extract the 8 imaging features for the one case that was left out. This was repeated 68 times until the features were extracted for each case. This approach was applied to avoid a possible bias caused by using the same images for training and testing of the algorithm. The features extracted in this way were then used for the survival analysis as described below. To test the main hypothesis of the study, we developed a Cox proportional hazards regression model including all imaging features as independent variables. A likelihood ratio test was used to establish whether there was a significant association between these features and overall survival. Specifically, the coxph function in R was used for this purpose. We also explored the association of individual features with survival. For multivariate analysis, we used the same Cox proportional hazards regression model to establish the significance of each individual feature. For the univariate analysis, we constructed a univariate Cox proportional hazards regression model for each variable individually and conducted a likelihood ratio test to establish whether there was a significant association between that variable and survival (R s coxph function was used). As an additional exploratory analysis, we used two imaging features indicated as significant in the analysis to divide the population of patients into four groups and we evaluated survival in each of these groups. Toward this goal, we binarized each variable such that the values higher than the median value of the variable for the population were changed to high and values lower or equal than median were changed to low. Then, four possible groups were established for the combinations of the values for the two variables. We plotted the survival curves for each of the groups and ran the log-rank test to compare the curves. Specifically, we used the survdiff function (with rho=0) in R for this purpose. 7

8 Results The distribution of values for each of the imaging features is presented on the histograms in Fig. 2. As expected, one can see generally higher values for the proportion of enhancement than for the proportion of necrosis. Even higher values can be observed for the T1/FLAIR ratio. The major axis length of the tumor was generally under 10 cm and the volume was under 200 cm 3. Table 1: Patient characteristics as well as follow up times. For continuous or semi-continuous variables, we provide mean and range. Characteristic Patients (n=68) Age at diagnosis (years) 59 (18-84) Sex Male 44 Female 24 Race/Ethnicity White 59 Black or African American 3 Asian 5 Not available 1 Follow up (days) 484 ( ) Deaths recorded 55 Regarding the main hypothesis of our study, the multivariate analysis showed that the automatically extracted image features were predictive of survival (p=0.031). Exploratory multivariate analysis for individual features indicated that two features were associated with survival: proportion of enhancing tumor (p = 0.013) and major axis length (p = 0.026). The univariate analysis confirmed these findings by indicating that the same two variables were associated with survival: proportion of enhancing tumor (p=0.021) and major axis length (p = 8

9 0.016). None of the other variables reached significance at the 0.05 level in the univariate or multivariate analyses. Fig. 2 Histograms of the extracted MR imaging features for the 68 study patients. Horizontal axes show feature values. For the variable Side, 1=Left, 2=Center/Bilateral, 3=Right. As additional preliminary analysis, we used the proportion of enhancing tumor and major axis length to divide our cohort of patients into four groups to establish whether any of these groups were associated with a worse or improved survival. The survival curves for each of the groups are presented in Fig. 3. One can see that the group with low major axis length and small proportion of enhancing tumor showed notably improved survival. The log rank test indicated that the survival curves in Fig. 3, were significantly different (p= ). 9

10 Fig. 3 Kaplan-Mayer curves for four patient groups determined based on major axis length and proportion of enhancing tumor Discussion In this paper we propose that computer-extracted preoperative MR imaging features can be used to predict survival time in GBM patients. We conducted an experiment with 68 subjects for whom we automatically extracted 8 imaging features and demonstrated that these features are associated with survival. The proportion of enhancing tumor and major axis length stood out as significant predictors of survival in multivariate and univariate analysis. The association of major 10

11 axis length with survival found in this study, while will require additional validation, adds to only limited prior data on importance of this feature [15, 16]. We believe that the proposed approach is a significant step toward a more systematic use of MR imaging in GBM survival prognosis. The proposed approach is very practical in that it does not require additional work from the radiologist interpreting the image. The advantages of our approach are the following. First, it relieves a radiologist from the burden of assessing multiple additional features in the imaging study. This would decrease the cost of a prognostic biomarker based on our approach. Second, we offer a quantitative approach to feature assessment. Specifically, the volumetric measurements are performed precisely using computer algorithms and do not rely on an approximate assessment by a radiologist. Related to this, our approach is free of inter-observer variability. Finally, while in this study we have evaluated only simple features, in general the computer-based approach allows for the assessment of a large number of features, some of which might not be easily perceptible to human eye. Examples include texture features. However, additional experiments are necessary to evaluate the prognostic value of such features. We envision that the feature extraction and survival prediction software would be embedded into the imaging equipment and the survival prognosis would be provided automatically to the clinician along with the actual imaging study. Our study provides a proof of concept that the utilization of GBM MR images in such manner is possible. While our study provides a proof of concept for the automatic approach survival prognosis based on MR imaging, significant further development is needed to improve such prediction. Specifically, our study is limited to only 8 relatively simple features. A multitude of additional features could be extracted (e.g. texture features), some of which might be related to survival. The evaluation of such additional features will require study with a larger number of patients. Regarding the two features that were shown to be associated with survival in our study, the proportion of enhancing tumor and major axis length of the tumor, our finding is consistent with previously reported findings where manually extracted equivalents of these features were found to be strong predictors of survival [15]. Our additional exploratory analysis of the model with just these two variables showed that a group associated with low major axis length and low proportion of enhancing tumor is associated with a notable improvement in survival. While this finding should be confirmed with more analysis including a larger database of patients, it shows potential for a simple automated imaging biomarker for survival prognosis. 11

12 Our experiments showed some robustness of our approach. Specifically, in the evaluation process, we included data from two different institutions with varying presentations of different compartments in the MR images. Such variability makes the automatic segmentation of different tumor compartments more difficult. However, regardless of this variability, the features extracted by our algorithm remained significant predictors of survival. Our study has some limitations. One of them is a limited sample size (n=68). A larger sample size could unveil additional variable significant in predicting survival. Please note, however, that the sample size used in our study is not unusual for this kind of investigation. Please also note that our study required annotation of four different tumor compartments of each slice of each case which required enormous amount of radiologist work. We are not aware of a study using similar data for 68 patients. Furthermore, our proof-of-concept study does not include clinical and treatment variables such as age, Karnofsky performance status, or type of surgery. Future studies with larger sample size will include such variables. To conclude, in this study, we presented a proof of concept for using computer-extracted imaging features to predict survival in GBM. While further studies are necessary, our approach was shown to be promising. Conflict of Interest: Dr. Maciej A. Mazurowski receives grant funding from the Department of Defense Breast Cancer Research Program. He also receives consulting fees from American College of Radiology Image Metrix (contractor to GE) for his services as a scientific consultant. Jing Zhang, Katherine B. Peters, and Hasan Hobbs have no conflicts of interest to declare. REFERENCES 1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in Neuro- Oncology. 2012;14(suppl 5):v1-v Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology. 2009;10(5):

13 3. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 2005;352(10): Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Journal of neurosurgery. 2001;95(2): Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of Clinical Oncology. 2010;28(24): McDonald KL, Aw G, Kleihues P. Role of biomarkers in the clinical management of glioblastomas: What are the barriers and how can we overcome them? Frontiers in neurology. 2012;3. 7. Verhaak RG, Hoadley KA, Purdom E, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer cell. 2010;17(1): Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro-oncology. 2010;12(1): Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine. 2009;360(8): Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial /CE. 3. The lancet oncology. 2008;9(1): Rivera AL, Pelloski CE, Gilbert MR, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-oncology. 2010;12(2): Minniti G, Salvati M, Arcella A, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. Journal of neuro-oncology. 2011;102(2): Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. American journal of neuroradiology. 2005;26(10): Zinn PO, Sathyan P, Mahajan B, et al. A novel volume-age-kps (VAK) glioblastoma classification identifies a prognostic cognate microrna-gene signature. PLoS One. 2012;7(8):e Gutman DA, Cooper LA, Hwang SN, et al. MR Imaging Predictors of Molecular Profile and Survival: Multi-institutional Study of the TCGA Glioblastoma Data Set. Radiology

14 16. Mazurowski MA, Desjardins A, Malof JM. Imaging descriptors improve the predictive power of survival models for glioblastoma patients. Neuro-oncology. 2013;15(10): Zacharaki E, Morita N, Bhatt P, O'Rourke D, Melhem E, Davatzikos C. Survival Analysis of Patients with High-Grade Gliomas Based on Data Mining of Imaging Variables. American Journal of Neuroradiology. 2012;33(6): Zhou M, Hall LO, Goldgof DB, Gillies RJ, Gatenby RA. Survival time prediction of patients with glioblastoma multiforme tumors using spatial distance measurement. SPIE Medical Imaging: International Society for Optics and Photonics, 2013; p O-O Popuri K, Cobzas D, Murtha A, Jägersand M. 3D variational brain tumor segmentation using Dirichlet priors on a clustered feature set. International journal of computer assisted radiology and surgery. 2012;7(4): Zhu Y, Young GS, Xue Z, et al. Semi-automatic segmentation software for quantitative clinical brain glioblastoma evaluation. Academic Radiology. 2012;19(8): Zikic D, Glocker B, Konukoglu E, et al. Decision forests for tissue-specific segmentation of high-grade gliomas in multi-channel MR. Medical Image Computing and Computer-Assisted Intervention MICCAI 2012: Springer, 2012; p Zhang J, Barboriak DP, Hobbs H, Mazurowski MA. A fully automatic extraction of magnetic resonance image features in Glioblastoma patients. Medical Physics. 2013; 41(4):

Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study

Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester

More information

Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features

Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features Hugo J.W.L. Aerts, Harvard University Emmanuel Rios Velazquez, Harvard University Raphael Meier,

More information

This study was designed to evaluate an online prognosis

This study was designed to evaluate an online prognosis Neuro-Oncology 15(8):1074 1078, 2013. doi:10.1093/neuonc/not033 Advance Access publication March 29, 2013 NEURO-ONCOLOGY Can the prognosis of individual patients with glioblastoma be predicted using an

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly

More information

Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study

Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study ORIGINAL ARTICLE Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study E.R. Morgan md,* A. Norman md, K. Laing md, and M.D. Seal md ABSTRACT Purpose

More information

Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study

Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:

More information

Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma

Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional

More information

Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment

Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Jennifer Wright Neurosurgery SSC Audit Team Jennifer Wright, Rachel Tresman, Cyril Dubois, Surash Surash,

More information

Clinical Trials for Adult Brain Tumors - the Imaging Perspective

Clinical Trials for Adult Brain Tumors - the Imaging Perspective Clinical Trials for Adult Brain Tumors - the Imaging Perspective Whitney B. Pope, M.D., Ph.D. Department of Radiology David Geffen School of Medicine at UCLA August 22, 2015 1 Disclosure of Financial Relationships

More information

Precision medicine for gliomas

Precision medicine for gliomas Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,

More information

for the TCGA Breast Phenotype Research Group

for the TCGA Breast Phenotype Research Group Decoding Breast Cancer with Quantitative Radiomics & Radiogenomics: Imaging Phenotypes in Breast Cancer Risk Assessment, Diagnosis, Prognosis, and Response to Therapy Maryellen Giger & Yuan Ji The University

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas

More information

Accepted: 13 June 2018

Accepted: 13 June 2018 Received: 26 February 2018 Revised: 12 June 2018 DOI: 10.1002/cam4.1666 Accepted: 13 June 2018 ORIGINAL RESEARCH The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized

More information

3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors

3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors research article 213 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors Yilmaz Tezcan and Mehmet Koc Department

More information

Prognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status.

Prognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status. Prognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status. R. Zalazar, M.D. Hernández, M. Páramo, P. Slon, M. Millor Muruzabal, J. Solorzano

More information

Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide

Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide University of Zurich Zurich Open Repository and Archive Winterthurerstr. 19 CH-857 Zurich http://www.zora.uzh.ch Year: 29 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine

More information

Advances in Brain Tumor Research: Leveraging BIG data for BIG discoveries

Advances in Brain Tumor Research: Leveraging BIG data for BIG discoveries Advances in Brain Tumor Research: Leveraging BIG data for BIG discoveries Jill Barnholtz-Sloan, PhD Associate Professor & Associate Director for Bioinformatics and Translational Informatics jsb42@case.edu

More information

CaPTk: Cancer Imaging Phenomics Toolkit

CaPTk: Cancer Imaging Phenomics Toolkit CaPTk: Cancer Imaging Phenomics Toolkit Interaction Personalized Diagnostics CaPTk Quantitative Imaging Phenomic Features Radiogenomics Image Analysis Machine Learning What is CaPTk? A dynamically growing

More information

University of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010

University of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010 University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,

More information

Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide

Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2009 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine

More information

To analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma

To analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma To analyse whether ADC values have a correlation with survival or EGFR amplification status in glioblastoma R. Zalazar, M. Páramo, M. Hernández, P. Domínguez, J.Etxano, P.García Barquín, H.Quiceno Arias,

More information

Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme

Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme Adam J. Kole, MD, PhD 1 ; Henry S. Park, MD, MPH 1 ; Debra N. Yeboa, MD 1 ; Charles E. Rutter, MD 1 ; Christopher

More information

POC Brain Tumor Segmentation. vlife Use Case

POC Brain Tumor Segmentation. vlife Use Case Brain Tumor Segmentation vlife Use Case 1 Automatic Brain Tumor Segmentation using CNN Background Brain tumor segmentation seeks to separate healthy tissue from tumorous regions such as the advancing tumor,

More information

Diffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme

Diffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme Diffusion Restriction Precedes Contrast Enhancement in Glioblastoma Multiforme Adil Bata 1, Jai Shankar 2 1 Faculty of Medicine, Class of 2017 2 Department of Diagnostic Radiology, Division of Neuroradiology,

More information

Brain Tumors: Radiologic Perspective

Brain Tumors: Radiologic Perspective Brain Tumors: Radiologic Perspective Alberto Bizzi, M.D. Neuroradiology Humanitas Research Hospital Milan, Italy The job of the neuroradiologist in the work-up of brain tumors has quite changed in the

More information

The Prognostic Impact of Neutrophil Lymphocytic Ratio (NLR) on Survival of Patients with Glioblastoma Multiforme (GBM): A Retrospective Cohort Study

The Prognostic Impact of Neutrophil Lymphocytic Ratio (NLR) on Survival of Patients with Glioblastoma Multiforme (GBM): A Retrospective Cohort Study Cancer and Clinical Oncology; Vol. 6, No. 2; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education The Prognostic Impact of Neutrophil Lymphocytic Ratio (NLR) on Survival

More information

Clinical significance of FBXO17 gene expression in high-grade glioma

Clinical significance of FBXO17 gene expression in high-grade glioma Du et al. BMC Cancer (2018) 18:773 https://doi.org/10.1186/s12885-018-4680-3 RESEARCH ARTICLE Open Access Clinical significance of FBXO17 gene expression in high-grade glioma Di Du 1, Jian Yuan 2, Wencai

More information

See the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, An extent of resection threshold for newly diagnosed glioblastomas

See the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, An extent of resection threshold for newly diagnosed glioblastomas See the corresponding editorial in this issue, pp 1 2. J Neurosurg 115:3 8, 2011 An extent of resection threshold for newly diagnosed glioblastomas Clinical article Nader Sanai, M.D., 1 Mei-Yin Polley,

More information

MR-Radiomics in Neuro-Oncology

MR-Radiomics in Neuro-Oncology Klinik für Stereotaxie und funktionelle Neurochirurgie Institut für Neurowissenschaften und Medizin MR-Radiomics in Neuro-Oncology M. Kocher Klinik für funktionelle Neurochirurgie und Stereotaxie Forschungszentrum

More information

Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis

Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis G. Pesce 1, A. Bordoni, F. Montanaro, R. Renella 3, A. Richetti 1, D. Boscherini 3, S. Mauri 4,

More information

Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014

Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014 Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer

More information

ORIGINAL PAPERS. The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme

ORIGINAL PAPERS. The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme ORIGINAL PAPERS Adv Clin Exp Med 2015, 24, 2, 279 287 DOI: 10.17219/acem/40456 Copyright by Wroclaw Medical University ISSN 1899 5276 Anna Brzozowska 1, 2, A D, Anna Toruń 3, G, Maria Mazurkiewicz1, 2,

More information

Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma

Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Correlation With MGMT Promoter Methylation Status Alba A. Brandes, MD 1 ; Enrico Franceschi, MD 1 ; Alicia Tosoni,

More information

Differentiating Tumor and Edema in Brain Magnetic Resonance Images Using a Convolutional Neural Network

Differentiating Tumor and Edema in Brain Magnetic Resonance Images Using a Convolutional Neural Network Original Article Differentiating Tumor and Edema in Brain Magnetic Resonance Images Using a Convolutional Neural Network Aida Allahverdi 1, Siavash Akbarzadeh 1, Alireza Khorrami Moghaddam 2, Armin Allahverdy

More information

Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma

Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma Original Article Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma Lin-Bo Cai, Juan Li, Ming-Yao Lai, Chang-Guo Shan, Zong-De Lian, Wei-Ping Hong, Jun-Jie Zhen,

More information

GBM heterogeneity characterization by radiomic analysis of phenotype anatomical planes

GBM heterogeneity characterization by radiomic analysis of phenotype anatomical planes GBM heterogeneity characterization by radiomic analysis of phenotype anatomical planes Ahmad Chaddad *, Christian Desrosiers, Matthew Toews Laboratory for Imagery, Vision and Artificial Intelligence, Ecole

More information

Related Policies None

Related Policies None Medical Policy MP 2.04.113 BCBSA Ref. Policy: 2.04.113 Last Review: 05/30/2018 Effective Date: 05/30/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational

More information

2015 EUROPEAN CANCER CONGRESS

2015 EUROPEAN CANCER CONGRESS 2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th

More information

Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy

Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy Christine N Chang-Halpenny, MD; Jekwon Yeh, MD; Winston W Lien, MD

More information

Somatic mutations associated with MRI-derived volumetric features in glioblastoma

Somatic mutations associated with MRI-derived volumetric features in glioblastoma DOI 10.1007/s00234-015-1576-7 DIAGNOSTIC NEURORADIOLOGY Somatic mutations associated with MRI-derived volumetric features in glioblastoma David A. Gutman 1,2 & William D. Dunn Jr 1,2 & Patrick Grossmann

More information

RADIOGENOMIC CORRELATION FOR PROGNOSIS IN PATIENTS WITH GLIOBLASTOMA MULTIFORMAE. A Thesis. Presented to the. Faculty of. San Diego State University

RADIOGENOMIC CORRELATION FOR PROGNOSIS IN PATIENTS WITH GLIOBLASTOMA MULTIFORMAE. A Thesis. Presented to the. Faculty of. San Diego State University RADIOGENOMIC CORRELATION FOR PROGNOSIS IN PATIENTS WITH GLIOBLASTOMA MULTIFORMAE A Thesis Presented to the Faculty of San Diego State University In Partial Fulfillment of the Requirements for the Degree

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION

More information

Contemporary Management of Glioblastoma

Contemporary Management of Glioblastoma Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I

More information

Computer based delineation and follow-up multisite abdominal tumors in longitudinal CT studies

Computer based delineation and follow-up multisite abdominal tumors in longitudinal CT studies Research plan submitted for approval as a PhD thesis Submitted by: Refael Vivanti Supervisor: Professor Leo Joskowicz School of Engineering and Computer Science, The Hebrew University of Jerusalem Computer

More information

Zurich Open Repository and Archive

Zurich Open Repository and Archive University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Nomograms for predicting survival of patients with newly diagnosed glioblastoma:

More information

Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients

Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients Manal Nicolasjilwan, University of Virginia Health System Ying Hu, National Cancer Institute

More information

Going Past the Data for Temozolomide. J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D.

Going Past the Data for Temozolomide. J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D. Going Past the Data for Temozolomide J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D. Departments of Medicine (JLV), Neurosurgery (JLV) and Pharmacy Practice (LRB)

More information

Hypofractionated radiation therapy for glioblastoma

Hypofractionated radiation therapy for glioblastoma Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health

More information

Cilengitide (Impetreve) for glioblastoma multiforme. February 2012

Cilengitide (Impetreve) for glioblastoma multiforme. February 2012 Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

Knowledge Discovery and Predictive Modeling from Brain Tumor MRIs

Knowledge Discovery and Predictive Modeling from Brain Tumor MRIs University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School September 2015 Knowledge Discovery and Predictive Modeling from Brain Tumor MRIs Mu Zhou University of South

More information

Nature Methods: doi: /nmeth.3115

Nature Methods: doi: /nmeth.3115 Supplementary Figure 1 Analysis of DNA methylation in a cancer cohort based on Infinium 450K data. RnBeads was used to rediscover a clinically distinct subgroup of glioblastoma patients characterized by

More information

8/1/2017. Imaging and Molecular Biomarkers of Lung Cancer Prognosis. Disclosures. The Era of Precision Oncology

8/1/2017. Imaging and Molecular Biomarkers of Lung Cancer Prognosis. Disclosures. The Era of Precision Oncology Imaging and Molecular Biomarkers of Lung Cancer Prognosis Ruijiang Li, PhD Assistant Professor of Radiation Oncology 08/01/2017 Stanford University Department of Radiation Oncology School of Medicine Disclosures

More information

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer

More information

DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES

DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES Marco Krengli Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale A. Avogadro THE STANDARD OF CARE

More information

Low grade glioma: a journey towards a cure

Low grade glioma: a journey towards a cure Editorial Page 1 of 5 Low grade glioma: a journey towards a cure Ali K. Choucair SIU School of Medicine, Springfield, IL, USA Correspondence to: Ali K. Choucair, MD. Professor of Neurology, Director of

More information

21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare

21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology

More information

Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121

Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2018. All rights reserved.

More information

Institute of Oncology & Radiobiology. Havana, Cuba. INOR

Institute of Oncology & Radiobiology. Havana, Cuba. INOR Institute of Oncology & Radiobiology. Havana, Cuba. INOR 1 Transition from 2-D 2 D to 3-D 3 D conformal radiotherapy in high grade gliomas: : our experience in Cuba Chon. I, MD - Chi. D, MD - Alert.J,

More information

PRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study

PRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study NOTE: Consider Clinical Trials as treatment options for eligible patients. Page 1 of 6 RADIOLOGICAL PRESENTATION PRESURGICAL PLANNING TREATMENT Imaging study suggestive of glioma 1 Left hemisphere speech/motor

More information

National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008

National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008 Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS

UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN

More information

Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma 1

Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma 1 This copy is for personal use only. To order printed copies, contact reprints@rsna.org Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma

More information

Antiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /

Antiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. / Antiangiogenic drugs in unresectable glioblastoma Dra. Carmen Balañá. / Outcome for unresectable GBM Overall survival for unresectable GBM without further treatment is: 3 months at most. Radiotherapy increases

More information

Supplemental Information. Molecular, Pathological, Radiological, and Immune. Profiling of Non-brainstem Pediatric High-Grade

Supplemental Information. Molecular, Pathological, Radiological, and Immune. Profiling of Non-brainstem Pediatric High-Grade Cancer Cell, Volume 33 Supplemental Information Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial Alan Mackay,

More information

Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.

Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit

More information

Prognosis Classification in Glioblastoma Multiforme using Multimodal MRI Derived Heterogeneity Textural Features: Impact of Pre-processing Choices

Prognosis Classification in Glioblastoma Multiforme using Multimodal MRI Derived Heterogeneity Textural Features: Impact of Pre-processing Choices Prognosis Classification in Glioblastoma Multiforme using Multimodal MRI Derived Heterogeneity Textural Features: Impact of Pre-processing Choices Taman Upadhaya ad, Yannick Morvan a, Eric Stindel bd,

More information

MRI-Based Biomarkers of Therapeutic Response in Triple-Negative Breast Cancer

MRI-Based Biomarkers of Therapeutic Response in Triple-Negative Breast Cancer MRI-Based Biomarkers of Therapeutic Response in Triple-Negative Breast Cancer Daniel Golden Postdoctoral Scholar (Radiology) Stanford University Daniel Rubin Laboratory NCI Cancer Imaging Fellowship Seminar

More information

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 Limited role for extended maintenance temozolomide for newly diagnosed

More information

Lynn S. Ashby 1*, Kris A. Smith 2 and Baldassarre Stea 3

Lynn S. Ashby 1*, Kris A. Smith 2 and Baldassarre Stea 3 Ashby et al. World Journal of Surgical Oncology (2016) 14:225 DOI 10.1186/s12957-016-0975-5 REVIEW Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide

More information

Efficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis

Efficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis Efficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis Igal Kushnir MD 1 * and Tzahala Tzuk-Shina MD 2 1 Oncology Insitute, Tel Aviv Sourasky Medical Center,

More information

MEETING SUMMARY ASH 2018, San Diego, USA

MEETING SUMMARY ASH 2018, San Diego, USA MEETING SUMMARY ASH 2018, San Diego, USA Prof. Stefano Luminari University of Modena and Reggio Emilia, Italy AN UPDATE ON PROGNOSTIC FACTORS IN INDOLENT LYMPHOMAS 2 DISCLAIMER Please note: The views expressed

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING

More information

Predictive Biomarkers in GBM

Predictive Biomarkers in GBM Predictive Biomarkers in GBM C. David James, Ph.D. Professor & Associate Director, Brain Tumor Research Center Dept. Neurological Surgery and Helen Diller Comprehensive Cancer Center, University of California

More information

Appraisal of carmustine. implants and temozolomide. for newly diagnosed high. Brain and Spine Foundation

Appraisal of carmustine. implants and temozolomide. for newly diagnosed high. Brain and Spine Foundation Appraisal of carmustine implants and temozolomide for newly diagnosed high grade glioma Brain and Spine Foundation June 2005 Submission to the National Institute for Health and Clinical Excellence Brain

More information

RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA

RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA MULTIFORM GEINO 2014 Dra Estela Pineda Madrid Hospital Clínic Barcelona EGFRvIII in glioblastoma multiform The most common mutation of EGFR in GBM Expressed in 30%

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bredel M, Scholtens DM, Yadav AK, et al. NFKBIA deletion in

More information

Translating MRS into clinical benefit for children with brain tumours

Translating MRS into clinical benefit for children with brain tumours Translating MRS into clinical benefit for children with brain tumours Andrew Peet NIHR Research Professor Childhood Cancer The Facts Cancer is the most common cause of death from disease in childhood Brain

More information

Early postoperative tumor progression predicts clinical outcome in glioblastoma implication for clinical trials

Early postoperative tumor progression predicts clinical outcome in glioblastoma implication for clinical trials J Neurooncol (2017) 132:249 254 DOI 10.1007/s11060-016-2362-z CLINICAL STUDY Early postoperative tumor progression predicts clinical outcome in glioblastoma implication for clinical trials Andreas Merkel

More information

Retrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease

Retrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (5), Page 4551-4555 Retrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease

More information

The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients survival: a metaanalysis

The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients survival: a metaanalysis Zhao et al. World Journal of Surgical Oncology (2016) 14:261 DOI 10.1186/s12957-016-1012-4 REVIEW The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients survival:

More information

Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide

Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide 405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD

More information

Arecent randomized controlled trial (RCT) established

Arecent randomized controlled trial (RCT) established Neuro-Oncology 12(2):190 198, 2010. doi:10.1093/neuonc/nop004 NEURO-ONCOLOGY The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme Rose Lai, Dawn L. Hershman,

More information

University of Alberta. Maysam Heydari. Master of Science. Department of Computing Science

University of Alberta. Maysam Heydari. Master of Science. Department of Computing Science University of Alberta PROGNOSIS OF GLIOBLASTOMA MULTIFORME USING TEXTURAL PROPERTIES ON MRI by Maysam Heydari A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of

More information

Prognostic value of baseline MRI in Glioblastoma Multiforme patients: a survival analysis of morphological, volumetric and diffusion MRI predictors

Prognostic value of baseline MRI in Glioblastoma Multiforme patients: a survival analysis of morphological, volumetric and diffusion MRI predictors Prognostic value of baseline MRI in Glioblastoma Multiforme patients: a survival analysis of morphological, volumetric and diffusion MRI predictors Poster No.: C-1179 Congress: ECR 2016 Type: Authors:

More information

Survival Analysis of Glioblastoma Multiforme

Survival Analysis of Glioblastoma Multiforme DOI:10.22034/APJCP.2018.19.9.2613 RESEARCH ARTICLE Editorial Process: Submission:04/24/2018 Acceptance:08/19/2018 Supapan Witthayanuwat, Montien Pesee*, Chunsri Supaadirek, Narudom Supakalin, Komsan Thamronganantasakul,

More information

성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)

성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015) 성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating

More information

DOWNLOAD OR READ : THE GLIOMA BOOK PDF EBOOK EPUB MOBI

DOWNLOAD OR READ : THE GLIOMA BOOK PDF EBOOK EPUB MOBI DOWNLOAD OR READ : THE GLIOMA BOOK PDF EBOOK EPUB MOBI Page 1 Page 2 the glioma book the glioma book pdf the glioma book A glioma is a type of tumor that starts in the glial cells of the brain or the spine.

More information

BRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER

BRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER BRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER Kathryn M Field and Mark A Rosenthal Department of Medical Oncology, Royal Melbourne Hospital, Victoria, Australia.

More information

Glioblastoma (GBM) is the most common and. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients

Glioblastoma (GBM) is the most common and. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients CLINICAL ARTICLE J Neurosurg 127:132 138, 2017 Bone marrow response as a potential biomarker of outcomes in glioblastoma patients *Eugene J. Vaios, AB, 1,5 Brian V. Nahed, MD, MSc, 1,5 Alona Muzikansky,

More information

Applying Tissue Phenomics to Colorectal Clinical Questions

Applying Tissue Phenomics to Colorectal Clinical Questions Applying Tissue Phenomics to Colorectal Clinical Questions International Symposium for Tissue Phenomics San Francisco October 2014 Peter Caie Senior Research Fellow University of St Andrews Systems Pathology

More information

Application of Tumor Treating Fields for Newly Diagnosed Glioblastoma Multiforme: Understanding of National Practice Patterns and Trends

Application of Tumor Treating Fields for Newly Diagnosed Glioblastoma Multiforme: Understanding of National Practice Patterns and Trends Application of Tumor Treating Fields for Newly Diagnosed Glioblastoma Multiforme: Understanding of National Practice Patterns and Trends Shearwood McClelland III, M.D. Department of Radiation Medicine

More information

Medical Image Mining in the Era of Big Data and Deep Learning

Medical Image Mining in the Era of Big Data and Deep Learning Medical Image Mining in the Era of Big Data and Deep Learning Lawrence O. Hall Department of Computer Science & Engineering University of South Florida Tampa, FL. 33620-9951 lohall@mail.usf.edu Collaborators

More information

ACTR-46. Presented at the Society for Neuro-Oncology Annual Scientific Meeting, November 16-19, 2017; San Francisco, CA, USA

ACTR-46. Presented at the Society for Neuro-Oncology Annual Scientific Meeting, November 16-19, 2017; San Francisco, CA, USA ACTR-46 AG-120, A First-in-Class Mutant IDH1 Inhibitor in Patients with Recurrent or Progressive IDH1 Mutant Glioma: Updated Results from the Phase 1 Non-Enhancing Glioma Population Ingo K. Mellinghoff

More information

University of Alberta. Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers

University of Alberta. Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers University of Alberta Evaluation of Concomitant Temozolomide Treatment in Glioblastoma Multiforme Patients in Two Canadian Tertiary Care Centers by Ibrahim Alnaami A thesis submitted to the Faculty of

More information

Motivating the Additional Use of External Validity: Examining Transportability in a Model of Glioblastoma Multiforme

Motivating the Additional Use of External Validity: Examining Transportability in a Model of Glioblastoma Multiforme Motivating the Additional Use of External Validity: Examining Transportability in a Model of Glioblastoma Multiforme Abstract Kyle W. Singleton 1,2, William Speier 1,2, Alex AT Bui PhD 1,2, William Hsu

More information

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The National Surgical

More information

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors

More information

Citation Pediatrics international (2015), 57.

Citation Pediatrics international (2015), 57. Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation

More information

Oncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013

Oncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013 Oncological Management of Brain Tumours Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013 Outline General considerations of Primary Brain Tumours: epidemiology, pathology, presentation. Diagnosis

More information

doi: /bjr/

doi: /bjr/ doi: 10.1259/bjr/29022270 Prognostic factors in the consecutive institutional series of glioblastoma multiforme patients who received high-dose particle radiotherapy or conventional radiotherapy Masahide

More information